---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-24-009003"
form_type: "8-K/A"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T16:51:16.691024+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix expects $50M non-cash impairment on decommissioned ADC facility in Q2 2024

## Summary
- Non-cash impairment charge of ~$50M to be recognized in Q2 2024 financial statements.
- Facility is a 45,000 sq ft bio-safety level-2 plant in Dartmouth, MA, previously intended for live-virus vaccine manufacturing.
- Impairment assumes general industrial use, not GMP; equipment appraised; brokerage firm retained to find buyer.
- Company states impairment will not affect future operations, liquidity, or cash flows.
- Decommissioning aligns with strategic focus on Tonmya (TNX-102 SL) for fibromyalgia.

## SEC filing metadata
- accession: 0001999371-24-009003
- form_type: 8-K/A
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.06, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937124009003/0001999371-24-009003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937124009003/tnxp-8ka_072424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-24-009003
- JSON: https://secwatch.observer/filing/0001999371-24-009003.json
- Plain text: https://secwatch.observer/filing/0001999371-24-009003.txt

## Key facts
- Restructurings & Charges
  Tonix Pharmaceuticals Holding Corp. announced a impairment with charges of approximately $50 million affecting Advanced Development Center in Dartmouth, Massachusetts.
  - Type: impairment
  - Charge: approximately $50 million
  - Affected area: Advanced Development Center in Dartmouth, Massachusetts
  source text: the Company expects that the financial statements for the quarter ended June 30, 2024 will reflect a non-cash impairment in the amount of approximately $50 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000199937124009003/0001999371-24-009003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.